Statements (53)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
NMDA receptor antagonist recreational drug dissociative drug |
| gptkbp:boilingPoint |
136-137°C (at 0.5 mmHg)
|
| gptkbp:CASNumber |
77-10-1
|
| gptkbp:chemicalFormula |
C17H25N
|
| gptkbp:detects |
urine drug test
|
| gptkbp:developedBy |
gptkb:Parke-Davis
|
| gptkbp:developedInYear |
1956
|
| gptkbp:effect |
gptkb:center
hypertension numbness dissociation tachycardia euphoria hallucinations agitation analgesia delusions seizures (in overdose) |
| gptkbp:eliminationHalfLife |
7-46 hours
|
| gptkbp:excretion |
urine
|
| gptkbp:hasStreet |
ozone
rocket fuel angel dust embalming fluid supergrass wack |
| https://www.w3.org/2000/01/rdf-schema#label |
phencyclidine
|
| gptkbp:isAbusedAs |
recreational drug
|
| gptkbp:isPrecursorFor |
gptkb:ketamine
|
| gptkbp:isProhibitedIn |
most countries
|
| gptkbp:IUPACName |
1-(1-phenylcyclohexyl)piperidine
|
| gptkbp:legalStatus |
Class A drug (UK)
Schedule II controlled substance (US) Schedule I controlled substance (Canada) |
| gptkbp:meltingPoint |
46-47°C
|
| gptkbp:metabolism |
liver
|
| gptkbp:molecularWeight |
243.39 g/mol
|
| gptkbp:riskFactor |
addiction
psychosis neurotoxicity violent behavior |
| gptkbp:routeOfAdministration |
smoking
oral inhalation intravenous |
| gptkbp:synonym |
gptkb:PCP
angel dust |
| gptkbp:usedAs |
anesthetic (historical)
|
| gptkbp:bfsParent |
gptkb:dextromethorphan
|
| gptkbp:bfsLayer |
6
|